• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

培加他汀钠治疗血管性活动性玻璃体视网膜病变患者的重要性。

The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy.

作者信息

Zhang Rui, Sun Xin, Niu Bo

机构信息

Physical Examination Department, Sino-Singapore Eco-City Hospital of Tianjin Medical University, Eco-City, Tianjin 300467, P.R. China.

Shanghai Institute of Cancer, Shanghai Jiaotong University School of Medicine, Shanghai 200240, P.R. China.

出版信息

Exp Ther Med. 2017 Dec;14(6):6002-6006. doi: 10.3892/etm.2017.5307. Epub 2017 Oct 16.

DOI:10.3892/etm.2017.5307
PMID:29285149
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5740564/
Abstract

The aim of the present study was to report the importance of pegaptanib sodium (PGSD) injection treatment for vascular active vitreoretinopathy (VAVR). A total of 82 patients with VAVR diagnosed by increasing subretinal exudation were enrolled and received a single intravitreal injection of PGSD. The efficacies of PGSD for patients with VAVR were analyzed using photography, fluorescein angiography and optical coherence tomography. The pathological changes in vascular activity, amount of exudation and visual acuity between the PGSD, and placebo group were also compared. The results demonstrated that the PGSD injection significantly decreased subretinal exudation and leakage compared with the placebo when assessed using fluorescein angiography in a 12-month follow-up. It was observed that the PGSD injection inhibited inflammatory cytokines interleukin-1β and tumor necrosis factor α for patients with VAVR compared with the placebo. Furthermore, results demonstrated that the average inflammation score and intraocular pressure was significantly decreased compared with the placebo. Visual acuity was improved from 1.3 to 0.7 in the majority of patients in the PGSD group. In conclusion, the outcomes of the present study indicate that the PGSD intravitreal injection is an efficient treatment option for patients with VAVR.

摘要

本研究的目的是报告培加他尼钠（PGSD）注射治疗血管性活动性玻璃体视网膜病变（VAVR）的重要性。共有82例经视网膜下渗出增加诊断为VAVR的患者入组，并接受了单次玻璃体内注射PGSD。使用摄影、荧光素血管造影和光学相干断层扫描分析PGSD对VAVR患者的疗效。还比较了PGSD组和安慰剂组之间血管活性、渗出量和视力的病理变化。结果表明，在12个月的随访中，使用荧光素血管造影评估时，与安慰剂相比，PGSD注射显著减少了视网膜下渗出和渗漏。观察到与安慰剂相比，PGSD注射对VAVR患者的炎性细胞因子白细胞介素-1β和肿瘤坏死因子α有抑制作用。此外，结果表明，与安慰剂相比，平均炎症评分和眼压显著降低。PGSD组大多数患者的视力从1.3提高到了0.7。总之，本研究结果表明，玻璃体内注射PGSD是VAVR患者的一种有效治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/2275dcc5107f/etm-14-06-6002-g09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/23c3a022320d/etm-14-06-6002-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/a28841fcbc47/etm-14-06-6002-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/ce547b56f1fe/etm-14-06-6002-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/d11eef799a1d/etm-14-06-6002-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/d85f4f23f6cc/etm-14-06-6002-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/81820c3aa168/etm-14-06-6002-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/34b655a561d3/etm-14-06-6002-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/4773ea52d70e/etm-14-06-6002-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/9ae06121a078/etm-14-06-6002-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/2275dcc5107f/etm-14-06-6002-g09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/23c3a022320d/etm-14-06-6002-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/a28841fcbc47/etm-14-06-6002-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/ce547b56f1fe/etm-14-06-6002-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/d11eef799a1d/etm-14-06-6002-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/d85f4f23f6cc/etm-14-06-6002-g04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/81820c3aa168/etm-14-06-6002-g05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/34b655a561d3/etm-14-06-6002-g06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/4773ea52d70e/etm-14-06-6002-g07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/9ae06121a078/etm-14-06-6002-g08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/5740564/2275dcc5107f/etm-14-06-6002-g09.jpg

相似文献

1
The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy.培加他汀钠治疗血管性活动性玻璃体视网膜病变患者的重要性。
Exp Ther Med. 2017 Dec;14(6):6002-6006. doi: 10.3892/etm.2017.5307. Epub 2017 Oct 16.
2
Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen).聚乙二醇化重组人血管内皮生长因子受体1拮抗剂（Macugen）治疗具有血管活性的家族性渗出性玻璃体视网膜病变
Retina. 2008 Mar;28(3 Suppl):S8-12. doi: 10.1097/IAE.0b013e3181679bf6.
3
Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.与新生血管性年龄相关性黄斑变性相关的视网膜下高反射性渗出物。
Retina. 2014 Jul;34(7):1281-8. doi: 10.1097/IAE.0000000000000166.
4
Management of CNV in angioid streaks by intravitreal use of specific anti-VEGF165 Aptamer (pegaptanib sodium): long-term results.通过玻璃体内使用特定的抗-VEGF165 Aptamer（帕塔尼单抗钠）治疗脉络膜新生血管性条纹：长期结果。
Curr Eye Res. 2011 May;36(5):492-5. doi: 10.3109/02713683.2011.560409.
5
Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.视网膜下高反射物质对抗血管内皮生长因子的可变反应，通过光学相干断层扫描血管造影进行分类。
Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2089-2096. doi: 10.1007/s00417-018-4121-7. Epub 2018 Sep 1.
6
CORRESPONDENCE OF LEAKAGE ON FLUORESCEIN ANGIOGRAPHY AND OPTICAL COHERENCE TOMOGRAPHY PARAMETERS IN DIAGNOSIS AND MONITORING OF MYOPIC CHOROIDAL NEOVASCULARIZATION TREATED WITH BEVACIZUMAB.贝伐单抗治疗近视性脉络膜新生血管的荧光素血管造影渗漏与光学相干断层扫描参数在诊断和监测中的相关性
Retina. 2016 Jan;36(1):104-9. doi: 10.1097/IAE.0000000000000684.
7
Intravitreal bevacizumab for treatment of peripapillary subretinal neovascularization.玻璃体内注射贝伐单抗治疗视乳头周围视网膜下新生血管形成
Retin Cases Brief Rep. 2008 Spring;2(2):145-7. doi: 10.1097/ICB.0b013e3181143854.
8
Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.前瞻性研究曲安奈德与贝伐单抗治疗视网膜中央静脉阻塞继发黄斑水肿。
Retina. 2011 May;31(5):838-45. doi: 10.1097/IAE.0b013e3181f4420d.
9
Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.在新生血管性年龄相关性黄斑变性中，pegaptanib或贝伐单抗治疗后光学相干断层扫描的定量比较。
Ophthalmology. 2008 Feb;115(2):347-354.e2. doi: 10.1016/j.ophtha.2007.03.082. Epub 2007 Jul 12.
10
Intravitreal pegaptanib sodium for Irvine-Gass syndrome.玻璃体内注射培加他尼钠治疗 Irvine-Gass 综合征。
Eur J Ophthalmol. 2008 Jan-Feb;18(1):138-41. doi: 10.1177/112067210801800125.

引用本文的文献

1
The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in Therapy.首个获批的适体药物——培加他尼（MacugenTM）二十周年：适体在治疗领域的历史、近期进展及未来前景
Pharmaceutics. 2025 Mar 20;17(3):394. doi: 10.3390/pharmaceutics17030394.

本文引用的文献

1
Anatomical and functional outcomes following vitrectomy for advanced familial exudative vitreoretinopathy: a single surgeon's experience.晚期家族性渗出性玻璃体视网膜病变玻璃体切除术后的解剖和功能结果：一位外科医生的经验
Br J Ophthalmol. 2017 Jul;101(7):946-950. doi: 10.1136/bjophthalmol-2016-309526. Epub 2016 Oct 28.
2
Intravitreal methotrexate infusion for proliferative vitreoretinopathy.玻璃体内注射甲氨蝶呤治疗增殖性玻璃体视网膜病变。
Clin Ophthalmol. 2016 Sep 19;10:1811-1817. doi: 10.2147/OPTH.S111893. eCollection 2016.
3
Expression of cyclooxygenases and trophic and growth factors in epiretinal membranes at late stages of proliferative vitreoretinopathy.
增殖性玻璃体视网膜病变晚期视网膜前膜中环氧化酶以及营养和生长因子的表达
Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2277-2279. doi: 10.1007/s00417-016-3445-4. Epub 2016 Aug 2.
4
Late development of a lamellar macular hole after the spontaneous separation of vitreoretinal traction: case report.玻璃体视网膜牵引自发分离后迟发性板层黄斑裂孔：病例报告
Eur J Ophthalmol. 2016 Nov 4;26(6):e168-e170. doi: 10.5301/ejo.5000785.
5
Vitreoretinal traction and lamellar macular holes associated with cicatricial toxoplasmic retinochoroiditis: case series report.与瘢痕性弓形体视网膜脉络膜炎相关的玻璃体视网膜牵拉和黄斑板层裂孔：病例系列报告
Eur J Ophthalmol. 2016 Aug 4;26(5):e128-33. doi: 10.5301/ejo.5000810.
6
[THE ROLE OF INFLAMMATION IN THE DEVELOPMENT OF PROLIFERATIVE VITREORETINOPATHY].[炎症在增殖性玻璃体视网膜病变发生发展中的作用]
Klin Med (Mosk). 2015;93(7):14-20.
7
Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis.类固醇作为孔源性视网膜脱离手术后降低增殖性玻璃体视网膜病变发生率的辅助治疗：一项系统评价和荟萃分析。
Drug Des Devel Ther. 2015 Mar 6;9:1393-400. doi: 10.2147/DDDT.S80983. eCollection 2015.
8
Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.血管内皮生长因子主要通过血小板衍生生长因子受体α发挥作用，以促进增殖性玻璃体视网膜病变。
Am J Pathol. 2014 Nov;184(11):3052-68. doi: 10.1016/j.ajpath.2014.07.026. Epub 2014 Sep 26.
9
Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by KIF11 mutations.家族性渗出性玻璃体视网膜病变和微小头畸形、淋巴水肿及脉络膜视网膜发育不良与 KIF11 突变相关的表型重叠。
JAMA Ophthalmol. 2014 Dec;132(12):1393-9. doi: 10.1001/jamaophthalmol.2014.2814.
10
Comment on 'Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy'.对“严重增生性玻璃体视网膜病变视网膜复位手术结束时玻璃体内注射贝伐单抗”的评论
Eye (Lond). 2014 Dec;28(12):1525. doi: 10.1038/eye.2014.198. Epub 2014 Aug 8.